Literature DB >> 21498115

No paradox, no progress: inverse cancer comorbidity in people with other complex diseases.

Rafael Tabarés-Seisdedos1, Nancy Dumont, Anaïs Baudot, Jose M Valderas, Joan Climent, Alfonso Valencia, Benedicto Crespo-Facorro, Eduard Vieta, Manuel Gómez-Beneyto, Salvador Martínez, John L Rubenstein.   

Abstract

In the past 5 years, several leading groups have attempted to explain why individuals with Down's syndrome have a reduced risk of many solid tumours and an increased risk of leukaemia and testicular cancer. Niels Bohr, the Danish physicist, noted that a paradox could initiate progress. We think that the paradox of a medical disorder protecting against cancer could be formalised in a new model of inverse cancer morbidity in people with other serious diseases. In this Personal View, we review evidence from epidemiological and clinical studies that supports a consistently lower than expected occurrence of cancer in patients with Down's syndrome, Parkinson's disease, schizophrenia, diabetes, Alzheimer's disease, multiple sclerosis, and anorexia nervosa. Intriguingly, most comorbidities are neuropsychiatric or CNS disorders. We provide a brief overview of evidence indicating genetic and molecular connections between cancer and these complex diseases. Inverse comorbidity could be a valuable model to investigate common or related pathways or processes and test new therapies, but, most importantly, to understand why certain people are protected from the malignancy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498115     DOI: 10.1016/S1470-2045(11)70041-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  61 in total

Review 1.  Menopause in multiple sclerosis: therapeutic considerations.

Authors:  Riley Bove; Tanuja Chitnis; Maria Houtchens
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

2.  Improving data and knowledge management to better integrate health care and research.

Authors:  M Cases; L I Furlong; J Albanell; R B Altman; R Bellazzi; S Boyer; A Brand; A J Brookes; S Brunak; T W Clark; J Gea; P Ghazal; N Graf; R Guigó; T E Klein; N López-Bigas; V Maojo; B Mons; M Musen; J L Oliveira; A Rowe; P Ruch; A Shabo; E H Shortliffe; A Valencia; J van der Lei; M A Mayer; F Sanz
Journal:  J Intern Med       Date:  2013-07-15       Impact factor: 8.989

Review 3.  Biomechanisms of Comorbidity: Reviewing Integrative Analyses of Multi-omics Datasets and Electronic Health Records.

Authors:  N Pouladi; I Achour; H Li; J Berghout; C Kenost; M L Gonzalez-Garay; Y A Lussier
Journal:  Yearb Med Inform       Date:  2016-11-10

4.  Shining a light on early stress responses and late-onset disease vulnerability.

Authors:  Mark F Mehler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-08       Impact factor: 11.205

Review 5.  Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review.

Authors:  Shantell C Nolen; Marcella A Evans; Avital Fischer; Maria M Corrada; Claudia H Kawas; Daniela A Bota
Journal:  Mech Ageing Dev       Date:  2017-05-11       Impact factor: 5.432

6.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

7.  Trade-off in the effect of the APOE gene on the ages at onset of cardiocascular disease and cancer across ages, gender, and human generations.

Authors:  Alexander M Kulminski; Irina Culminskaya; Konstantin G Arbeev; Svetlana V Ukraintseva; Liubov Arbeeva; Anatoli I Yashin
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

8.  The risk of amyotrophic lateral sclerosis after cancer in U.S. elderly adults: a population-based prospective study.

Authors:  D Michal Freedman; Jincao Wu; Sarah E Daugherty; Ralph W Kuncl; Lindsey R Enewold; Ruth M Pfeiffer
Journal:  Int J Cancer       Date:  2014-02-28       Impact factor: 7.396

Review 9.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

10.  Supramolecular nanofibrils inhibit cancer progression in vitro and in vivo.

Authors:  Yi Kuang; Xuewen Du; Jie Zhou; Bing Xu
Journal:  Adv Healthc Mater       Date:  2014-02-20       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.